{"id":"https://openalex.org/W2059909265","doi":"https://doi.org/10.1007/s13300-014-0087-6","title":"Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries","display_name":"Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries","alternate_titles":[],"publication_year":2014,"publication_date":"2014-11-03","ids":{"openalex":"https://openalex.org/W2059909265","doi":"https://doi.org/10.1007/s13300-014-0087-6","mag":"2059909265","pmid":"https://pubmed.ncbi.nlm.nih.gov/25366334","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4269654"},"language":"en","primary_location":{"id":"doi:10.1007/s13300-014-0087-6","doi":"https://doi.org/10.1007/s13300-014-0087-6","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13300-014-0087-6","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13300-014-0087-6.pdf","source":{"id":"https://openalex.org/S16535137","display_name":"Diabetes Therapy","issn_l":"1869-6961","issn":["1869-6961","1869-6953"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Therapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2059909265"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://link.springer.com/content/pdf/10.1007/s13300-014-0087-6.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065999728","display_name":"Victoria M. Divino","orcid":"https://orcid.org/0000-0001-5555-7912","observed_orcids":["https://orcid.org/0000-0001-5555-7912"]},"institutions":[{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Victoria Divino","raw_affiliation_strings":["Health Economics and Outcomes Research Real-World Evidence Solutions, IMS Health, Fairfax, VA, USA, vdivino@us.imshealth.com","IMS Health\u00ae"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economics and Outcomes Research Real-World Evidence Solutions, IMS Health, Fairfax, VA, USA, vdivino@us.imshealth.com","institution_ids":["https://openalex.org/I4210108991"]},{"raw_affiliation_string":"IMS Health\u00ae","institution_ids":["https://openalex.org/I4210108991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011077808","display_name":"Mitch DeKoven","orcid":"https://orcid.org/0000-0001-9346-6202","observed_orcids":["https://orcid.org/0000-0001-9346-6202"]},"institutions":[{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mitch DeKoven","raw_affiliation_strings":["Health Economics and Outcomes Research Real-World Evidence Solutions, IMS Health, Fairfax, VA, USA","IMS Health\u00ae"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economics and Outcomes Research Real-World Evidence Solutions, IMS Health, Fairfax, VA, USA","institution_ids":["https://openalex.org/I4210108991"]},{"raw_affiliation_string":"IMS Health\u00ae","institution_ids":["https://openalex.org/I4210108991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089397368","display_name":"Shawn Hallinan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shawn Hallinan","raw_affiliation_strings":["Health Economics and Outcomes Research Real-World Evidence Solutions, IMS Health, Fairfax, VA, USA","IMS Health\u00ae"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economics and Outcomes Research Real-World Evidence Solutions, IMS Health, Fairfax, VA, USA","institution_ids":["https://openalex.org/I4210108991"]},{"raw_affiliation_string":"IMS Health\u00ae","institution_ids":["https://openalex.org/I4210108991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029910628","display_name":"N. Varol","orcid":"https://orcid.org/0000-0003-4157-5962","observed_orcids":["https://orcid.org/0000-0003-4157-5962"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I4210095227","display_name":"Eli Lilly (United Kingdom)","ror":"https://ror.org/00psab413","country_code":"GB","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210095227"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Nebibe Varol","raw_affiliation_strings":["Global Patient Outcomes and Real World Evidence, Eli Lilly and Co, Surrey, UK","Eli Lilly and Co.#TAB#"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Patient Outcomes and Real World Evidence, Eli Lilly and Co, Surrey, UK","institution_ids":["https://openalex.org/I4210095227"]},{"raw_affiliation_string":"Eli Lilly and Co.#TAB#","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052498517","display_name":"Sara Bruce Wirta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara Bruce Wirta","raw_affiliation_strings":["Health Economics and Outcomes Research Real-World Evidence Solutions, IMS Health, Stockholm, Sweden","IMS Health\u00ae"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economics and Outcomes Research Real-World Evidence Solutions, IMS Health, Stockholm, Sweden","institution_ids":["https://openalex.org/I4210108991"]},{"raw_affiliation_string":"IMS Health\u00ae","institution_ids":["https://openalex.org/I4210108991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109402990","display_name":"Won Chan Lee","orcid":"https://orcid.org/0000-0001-7006-821X","observed_orcids":["https://orcid.org/0000-0001-7006-821X"]},"institutions":[{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Won Chan Lee","raw_affiliation_strings":["Health Economics and Outcomes Research Real-World Evidence Solutions, IMS Health, Fairfax, VA, USA","IMS Health\u00ae"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economics and Outcomes Research Real-World Evidence Solutions, IMS Health, Fairfax, VA, USA","institution_ids":["https://openalex.org/I4210108991"]},{"raw_affiliation_string":"IMS Health\u00ae","institution_ids":["https://openalex.org/I4210108991"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5009151561","display_name":"Matthew D. Reaney","orcid":"https://orcid.org/0000-0003-2918-722X","observed_orcids":["https://orcid.org/0000-0003-2918-722X"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I4210095227","display_name":"Eli Lilly (United Kingdom)","ror":"https://ror.org/00psab413","country_code":"GB","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210095227"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Matthew Reaney","raw_affiliation_strings":["Global Patient Outcomes and Real World Evidence, Eli Lilly and Co, Surrey, UK","Eli Lilly and Co.#TAB#"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Patient Outcomes and Real World Evidence, Eli Lilly and Co, Surrey, UK","institution_ids":["https://openalex.org/I4210095227"]},{"raw_affiliation_string":"Eli Lilly and Co.#TAB#","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5065999728"],"corresponding_institution_ids":["https://openalex.org/I4210108991"],"apc_list":{"value":7400,"currency":"USD","value_usd":7400},"apc_paid":{"value":7400,"currency":"USD","value_usd":7400},"fwci":2.9817,"has_fulltext":true,"cited_by_count":44,"citation_normalized_percentile":{"value":0.90682924,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"5","issue":"2","first_page":"499","last_page":"520"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9070000052452087},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9810000061988831},{"id":"https://openalex.org/keywords/exenatide-twice-daily","display_name":"exenatide twice daily","score":0.9120000004768372},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":1.0},{"id":"https://openalex.org/keywords/treatment-patterns","display_name":"treatment patterns","score":0.7390000224113464},{"id":"https://openalex.org/keywords/medication-persistence","display_name":"treatment persistence","score":0.843999981880188},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.7440000176429749},{"id":"https://openalex.org/keywords/treatment-switching","display_name":"treatment switching","score":0.44200000166893005},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.6600000262260437},{"id":"https://openalex.org/keywords/european-countries","display_name":"European countries","score":0.34200000762939453},{"id":"https://openalex.org/keywords/comparative-effectiveness","display_name":"comparative effectiveness","score":0.460999995470047},{"id":"https://openalex.org/keywords/antidiabetic-drugs","display_name":"antidiabetic drugs","score":0.48500001430511475},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.40299999713897705},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.47600001096725464}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8043261766433716},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.7401787638664246},{"id":"https://openalex.org/C185280430","wikidata":"https://www.wikidata.org/wiki/Q14909910","display_name":"Glucagon-like peptide 1 receptor","level":4,"score":0.6202058792114258},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.6197598576545715},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5853043794631958},{"id":"https://openalex.org/C2776398474","wikidata":"https://www.wikidata.org/wiki/Q424611","display_name":"Glucagon-like peptide-1","level":4,"score":0.5559216737747192},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5148417353630066},{"id":"https://openalex.org/C3018376624","wikidata":"https://www.wikidata.org/wiki/Q1100933","display_name":"Diabetes treatment","level":4,"score":0.5127350091934204},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.5119525194168091},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5095201134681702},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38271287083625793}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.1007/s13300-014-0087-6","doi":"https://doi.org/10.1007/s13300-014-0087-6","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13300-014-0087-6","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13300-014-0087-6.pdf","source":{"id":"https://openalex.org/S16535137","display_name":"Diabetes Therapy","issn_l":"1869-6961","issn":["1869-6961","1869-6953"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Therapy","raw_type":"journal-article"},{"id":"pmid:25366334","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25366334","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes therapy : research, treatment and education of diabetes and related disorders","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4269654","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4269654/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Ther","raw_type":"Text"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.775.2551","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.775.2551","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/fc/0b/13300_2014_Article_87.PMC4269654.pdf","raw_type":"text"}],"best_oa_location":{"id":"doi:10.1007/s13300-014-0087-6","doi":"https://doi.org/10.1007/s13300-014-0087-6","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13300-014-0087-6","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13300-014-0087-6.pdf","source":{"id":"https://openalex.org/S16535137","display_name":"Diabetes Therapy","issn_l":"1869-6961","issn":["1869-6961","1869-6953"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2059909265.pdf","grobid_xml":"https://content.openalex.org/works/W2059909265.grobid-xml"},"referenced_works_count":13,"referenced_works":["https://openalex.org/W62627980","https://openalex.org/W169596199","https://openalex.org/W1970905724","https://openalex.org/W1996134389","https://openalex.org/W2046858241","https://openalex.org/W2095682936","https://openalex.org/W2111876001","https://openalex.org/W2137106767","https://openalex.org/W2172193326","https://openalex.org/W2333363363","https://openalex.org/W2789732774","https://openalex.org/W4230892627","https://openalex.org/W4230942209"],"related_works":["https://openalex.org/W2570638938","https://openalex.org/W1966835776","https://openalex.org/W2866659336","https://openalex.org/W2942132427","https://openalex.org/W2793927060","https://openalex.org/W3153864446","https://openalex.org/W2896668644","https://openalex.org/W3108353055","https://openalex.org/W2586129535"],"abstract_inverted_index":{"INTRODUCTION:":[0],"The":[1,212],"objective":[2],"of":[3,12,142,149,266],"this":[4],"study":[5],"was":[6,97,176,200,218,259,274],"to":[7,206,225,248,269,281,318],"evaluate":[8],"real-world":[9],"treatment":[10,195],"patterns":[11,287],"type":[13],"2":[14],"diabetes":[15],"(T2D)":[16],"patients":[17,45,102,161,222,236],"initiating":[18,46],"glucagon-like":[19],"peptide-1":[20],"receptor":[21],"agonists":[22],"(GLP-1":[23],"RAs)":[24],"in":[25,164,271],"Germany":[26],"(GE),":[27],"the":[28,34,63,143,165,189,191,232,252,255],"United":[29],"Kingdom":[30],"(UK),":[31],"France":[32],"(FR),":[33],"Netherlands":[35],"(NE),":[36],"Belgium":[37],"(BE),":[38],"and":[39,76,84,92,106,113,120,131,158,181,183,209,283,303],"Sweden":[40],"(SE).":[41],"METHODS:":[42],"Adult":[43],"T2D":[44],"exenatide":[47,56],"twice":[48],"daily":[49,53],"(exBID),":[50],"liraglutide":[51],"once":[52,57],"(LIRA)":[54],"or":[55,151,228,299],"weekly":[58],"(exQW)":[59],"were":[60,122,162],"identified":[61],"using":[62],"IMS":[64,77],"LifeLink\u2122":[65],"(IMS":[66],"Health,":[67],"Danbury,":[68],"CT,":[69],"USA):":[70],"Electronic":[71],"Medical":[72],"Records":[73],"(EMR;":[74],"GE/UK/FR)":[75],"LifeLink\u2122:":[78],"longitudinal":[79],"prescriptions":[80],"(LRx;":[81],"NE/BE/GE/UK)":[82],"databases,":[83,190],"national":[85],"health":[86],"register":[87],"data":[88,308],"(SE),":[89],"between":[90],"2010":[91],"2012.":[93],"Therapy":[94],"initiation":[95],"date":[96],"termed":[98],"'index":[99],"date'.":[100],"Eligible":[101],"had":[103,237],"\u2265180-day":[104,115],"pre-":[105],"variable":[107],"follow-up":[108,175,316],"(minimum":[109],"\u2265360-day":[110],"post-index":[111,116],"exBID":[112,180,203,221,249,282],"LIRA,":[114,182],"exQW).":[117],"Treatment":[118,286],"modification":[119,196],"persistence":[121,294],"evaluated":[123,140],"over":[124],"180":[125,198,216],"days.":[126],"Kaplan-Meier":[127],"(KM)":[128],"survival":[129],"curves":[130],"Cox":[132,256],"proportional":[133],"hazards":[134],"models":[135],"(PHMs;":[136],"EMR":[137],"databases":[138],"only)":[139],"stopping":[141,241,267],"index":[144],"therapy":[145,242],"(measured":[146],"as":[147],"first":[148],"discontinuation":[150],"switch).":[152],"RESULTS:":[153],"30,206":[154],"exBID,":[155],"5,401":[156],"exQW,":[157],"52,155":[159],"LIRA":[160,207,226,235,258,298],"included":[163],"analysis":[166],"(46.0-66.9%":[167],"male;":[168],"mean":[169],"age":[170],"range":[171],"55.4-59.3":[172],"years).":[173],"Mean":[174],"20.3-27.4":[177],"months":[178,185],"for":[179,186],"7.6-13.9":[184],"exQW.":[187],"Across":[188],"proportion":[192,213,240],"experiencing":[193],"a":[194,238,262,277],"at":[197,215,243],"days":[199,217],"highest":[201,295],"among":[202,220,289,296,305],"(37.6-81.7%)":[204],"compared":[205,224,247,268,280],"(36.8-56.6%)":[208],"exQW":[210,229,273,300,315],"(32.3-47.7%).":[211],"persistent":[214],"lowest":[219,304],"(46.8-73.5%)":[223],"(50.6-80.1%)":[227],"(57.5-74.6%).":[230],"In":[231,254],"KM":[233],"analyses,":[234],"lower":[239,264,278],"all":[244],"time":[245],"points":[246],"patients,":[250,292],"across":[251,301],"databases.":[253],"PHMs,":[257],"associated":[260,275],"with":[261,276,293],"significantly":[263],"risk":[265,279],"exBID;":[270],"GE,":[272],"LIRA.":[284],"CONCLUSION:":[285],"varied":[288],"GLP-1":[290],"RA":[291],"either":[297],"countries,":[302],"exBID.":[306],"Longer-term":[307],"would":[309],"be":[310],"useful,":[311],"particularly":[312],"given":[313],"limited":[314],"due":[317],"more":[319],"recent":[320],"launch.":[321]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2059909265","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":9},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
